Maternal and Perinatal Pregnancy Outcome in Women With Heterozygous Hemoglobinopathies
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Feb 8, 2019
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • pregnant women with or without heterozygous hemoglobinopathy
- Exclusion Criteria:
- • refusal of study participation
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Zürich, , Switzerland
Patients applied
Trial Officials
Irene Hoesli, Prof. Dr. MD
Principal Investigator
Frauenklinik Universitätsspital Basel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials